Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study
Authors:
- 1 January 2010
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 116 (1) , 44-49
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Does Race Affect Postoperative Outcomes in Patients With Low-Risk Prostate Cancer Who Undergo Radical Prostatectomy?Urology, 2009
- Disparities in survival among women with invasive cervical cancerCancer, 2008
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by AktBritish Journal of Cancer, 2008
- Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2005
- Quality of Life Outcomes From a Randomized Phase III Trial of Cisplatin With or Without Topotecan in Advanced Carcinoma of the Cervix: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2005
- Neoadjuvant chemotherapy for cervical cancerExpert Opinion on Pharmacotherapy, 2003
- Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design.Journal of Clinical Oncology, 1998
- Current status of chemotherapy for cancer of the cervix.1992
- Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatinCancer, 1989